01066 Overview

Hong Kong Stock Market Performance: The Hong Kong stock market opened higher but closed lower, with the HSI down 384 points (1.4%) at 26,381, and total market turnover at HKD259.277 billion.

CKI Holdings' Stock Surge: A consortium led by CKI Holdings sold UKPN, resulting in a 4.5% increase in its stock price, while CKH Holdings and Power Assets also saw significant gains.

Tech Sector Declines: Alibaba's stock fell 3.6% after a report predicted weak quarterly profits, while other tech stocks like Tencent and Meituan also experienced declines.

Pharmaceuticals and Consumer Stocks Drop: Various pharmaceutical and consumer stocks saw significant losses, with declines ranging from 3.3% to 9.2% across multiple companies.

Healthcare Sector Outlook: Goldman Sachs predicts that the strong trend in China's healthcare sector will continue, with stock trading increasingly focused on companies' execution capabilities and R&D pipelines rather than just licensing expectations.

CDMO Companies Favorable: The broker is optimistic about CDMO companies due to their growth potential and reasonable valuations, upgrading WUXI APPTEC and WUXI XDC to Buy.

Selective Biotech and Pharma Strategy: Goldman Sachs favors biotech and pharmaceutical companies with promising data releases and transaction expectations, highlighting SKB BIO-B, HENLIUS, and HANSOH PHARMA as favorable investments.

Cautious on Medical Services: The broker maintains a neutral stance on the medical devices sector and is cautious about medical services due to cost control measures and weak consumption, downgrading HYGEIA HEALTH and JXR to Neutral/Sell.

Hong Kong Stock Market Decline: Hong Kong stocks experienced a significant decline, with the HSI dropping 580 points (2.08%) to close at 27,387, while the HSCEI and HSTECH also fell by 2.5% and 2.1%, respectively, amid a total market turnover of $301.612 billion.

Gold and Resource Stocks Performance: Spot gold prices fell over 5%, impacting several gold mining stocks, which tumbled between 10-14%. Resource stocks like Jiangxi Copper and MMG also saw declines of 9-10%, with Jiangxi Copper's short selling ratio reaching 28.3%.

Pharmaceutical Sector Developments: CSPC Pharma's stock dropped 10.2% despite a partnership with AstraZeneca for innovative medicines, involving an upfront payment exceeding $9.3 billion. Other pharma stocks also faced declines ranging from 3.3% to 4.9%.

Corporate News and Market Rumors: CKH Holdings fell 4.6% following a court ruling on port contracts, while New World Development's share price rose 2.2% amid rumors of a potential change in ownership involving Blackstone.

Market Performance: The NASDAQ Golden Dragon China Index rose over 4%, with Alibaba ADR leading the charge by climbing 10%, contributing to a strong opening for the Hong Kong bourse, which saw the HSI open 350 points higher and close the morning session up 268 points.

Technology Sector Movements: In the technology sector, notable stocks like BABA-W and ALI HEALTH saw gains of 3.5% and 3.3% respectively, while other major players like TENCENT and JD-SW also experienced slight increases, despite some stocks like MEITUAN-W and BIDU-SW declining.

Pharmaceutical Sector Highlights: The 44th JPMorgan Healthcare Conference commenced in San Francisco, with several Chinese pharmaceutical companies participating, leading to significant gains for stocks such as REMEGEN, which surged 11.6%, and CSPC PHARMA, which jumped 5.7% after its innovative drug application was accepted.

AI Concept Stocks Decline: Several AI concept stocks, including SENSETIME-W and WEIMOB INC, experienced declines ranging from 3.3% to 4.2%, while other stocks like KNOWLEDGE ATLAS and MINIMAX-WP saw even steeper drops of 8.8% and 7.5% respectively.

Market Performance: The HSI closed down 249 points (1%) at 25,220, with increased market turnover of HKD312.687 billion; several major stocks like JD-SW and BABA-W saw significant declines due to disappointing earnings reports.

Stock Movements: Notable gains were observed in JD HEALTH (+11.7%) and PA GOODDOCTOR (+8.1%), while other tech and pharma stocks also experienced mixed performances, reflecting varied investor sentiment across sectors.

Chinese Pharma Equipment Stocks Outlook: UBS anticipates a divergence in the performance of Chinese pharma equipment stocks in 2Q25 and 1H25, with domestic revenue expected to grow significantly from 3Q due to resumed bidding translating into revenue.

Market Trends and Recommendations: The report highlights ongoing differentiation in consumables and potential catalysts from China's healthcare policies, while maintaining a positive outlook for companies like United Imaging Healthcare and WEIGAO GROUP, both rated as Buy.